144 related articles for article (PubMed ID: 15462491)
1. IL-1RA in refractory systemic lupus erythematosus.
Moosig F; Zeuner R; Renk C; Schröder JO
Lupus; 2004; 13(8):605-6. PubMed ID: 15462491
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus.
Chang DM
Immunol Invest; 1997; 26(5-7):649-59. PubMed ID: 9399106
[TBL] [Abstract][Full Text] [Related]
4. Anakinra: a review of its use in the management of rheumatoid arthritis.
Waugh J; Perry CM
BioDrugs; 2005; 19(3):189-202. PubMed ID: 15984903
[TBL] [Abstract][Full Text] [Related]
5. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
6. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
[TBL] [Abstract][Full Text] [Related]
7. Anakinra treatment of patients with rheumatoid arthritis.
Calabrese LH
Ann Pharmacother; 2002; 36(7-8):1204-9. PubMed ID: 12086555
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
[TBL] [Abstract][Full Text] [Related]
9. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?
Capper ER; Maskill JK; Gordon C; Blakemore AI
Clin Exp Immunol; 2004 Nov; 138(2):348-56. PubMed ID: 15498048
[TBL] [Abstract][Full Text] [Related]
10. The trials of anakinra.
Burls A; Jobanputra P
Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
[No Abstract] [Full Text] [Related]
11. [Anakinra for therapy of rheumatoid arthritis].
Tomoo T; Sumida T
Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413
[No Abstract] [Full Text] [Related]
12. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.
Sturfelt G; Roux-Lombard P; Wollheim FA; Dayer JM
Br J Rheumatol; 1997 Dec; 36(12):1283-9. PubMed ID: 9448589
[TBL] [Abstract][Full Text] [Related]
13. Anakinra shows promise for treating patients with rheumatoid arthritis.
McIntosh T; Freeman TR
J Am Pharm Assoc (Wash); 2002; 42(4):660-2. PubMed ID: 12150367
[No Abstract] [Full Text] [Related]
14. [The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].
Riente L
Reumatismo; 2004; 56(1 Suppl 1):74-9. PubMed ID: 15201943
[TBL] [Abstract][Full Text] [Related]
15. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
16. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
Fleishmann RM
Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
[TBL] [Abstract][Full Text] [Related]
17. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity.
Suzuki H; Takemura H; Kashiwagi H
Arthritis Rheum; 1995 Aug; 38(8):1055-9. PubMed ID: 7639800
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
Bresnihan B; Alvaro-Gracia JM; Cobby M; Doherty M; Domljan Z; Emery P; Nuki G; Pavelka K; Rau R; Rozman B; Watt I; Williams B; Aitchison R; McCabe D; Musikic P
Arthritis Rheum; 1998 Dec; 41(12):2196-204. PubMed ID: 9870876
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
Jiang Y; Genant HK; Watt I; Cobby M; Bresnihan B; Aitchison R; McCabe D
Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
